Related Experiment Video
Updated: Mar 12, 2026
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
The Next Generation of Targeted Molecules for the Treatment of Chronic Lymphocytic Leukemia
Abstract:
With the recent approval of several new targeted therapies for chronic lymphocytic leukemia (CLL), there are now multiple options for its treatment. Inhibitors of Bruton tyrosine kinase (with ibrutinib being the first-in-class US Food and Drug Administration-approved agent) and phosphoinositide 3-kinase (with idelalisib as the first-in-class approved agent) are promising because they are generally well tolerated and highly effective against this malignancy. These agents may be particularly important in the treatment of older patients who are less able to tolerate the myelosuppression (and subsequent infections) associated with chemoimmunotherapy. As a class of medications, B-cell receptor inhibitors have some unique side effects, including redistribution lymphocytosis. Toxicities associated specifically with ibrutinib include increased risk for bleeding and atrial fibrillation. Idelalisib also has some unique toxicities: transaminitis, colitis, and pneumonitis. Targeted therapies recently approved for use in CLL include the novel anti-CD20 monoclonal antibodies obinutuzumab and ofatumumab, and the B-cell lymphoma 2 inhibitor venetoclax. This article describes the clinical data that led to approval of these B-cell receptor inhibitors for the treatment of CLL, and highlights newer agents in clinical development that target the same kinases as the currently available therapies.
Insights
New targeted therapies, including Bruton tyrosine kinase and phosphoinositide 3-kinase inhibitors, offer effective and well-tolerated treatment options for chronic lymphocytic leukemia (CLL), especially for older patients. These B-cell receptor inhibitors present unique side effect profiles requiring careful management.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Chronic lymphocytic leukemia (CLL) treatment landscape is evolving with new targeted therapies.
- Targeted agents offer alternatives to chemoimmunotherapy, particularly for elderly patients.
- B-cell receptor inhibitors represent a significant advancement in CLL management.
Purpose of the Study:
- To review clinical data supporting the approval of new targeted therapies for CLL.
- To highlight emerging B-cell receptor inhibitors and their mechanisms.
- To discuss the efficacy and tolerability of novel CLL treatments.
Main Methods:
- Review of clinical trial data for approved targeted therapies in CLL.
- Analysis of side effect profiles for Bruton tyrosine kinase and phosphoinositide 3-kinase inhibitors.
- Summary of ongoing clinical development for novel CLL agents.
Main Results:
- Several targeted therapies, including ibrutinib, idelalisib, obinutuzumab, ofatumumab, and venetoclax, are now approved for CLL.
- These agents demonstrate high efficacy and are generally well-tolerated, with distinct side effect profiles.
- Targeted therapies may be advantageous for older patients with CLL due to reduced myelosuppression.
Conclusions:
- New targeted therapies have expanded treatment options for CLL, offering improved outcomes and tolerability.
- Understanding the unique toxicities of agents like ibrutinib and idelalisib is crucial for patient management.
- Ongoing research continues to develop novel kinase inhibitors for CLL treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:24Modified-Release Drug Delivery Systems: Site-Targeted